nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-46358A01·Framework v5.13·Pipeline v0.4·Evaluated 13 Nov 2026·OECD: 3.1 Basic medicine·Subfield: Cell Biology·Basis: Full text·Type: Narrative review

Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature.

Silini et al.Silini, Di Pietro, Lang-Olip et al.·2020·Frontiers in bioengineering and biotechnology·10.3389/fbioe.2020.610544 ↗

Primary claim

The literature analysis we performed did not allow us to identify specific markers to uniquely identify the cell populations discussed herein. At the current time, this is a quasi impossible task due to the heterogeneity of the starting material

Supported · overlapping and culture-dependent markers support the bounded finding, although unreported literature selection limits completeness
In brief

An anatomically grounded perinatal-cell nomenclature roadmap extends earlier guidance, but unreported literature-selection and consensus procedures limit its authority as a standard.

ReliabilityNo concerns4 of 4 checks completeSee what was checked ↓
Abstract

Progress in the understanding of the biology of perinatal tissues has contributed to the breakthrough revelation of the therapeutic effects of perinatal derivatives (PnD), namely birth-associated tissues, cells, and secreted factors. The significant knowledge acquired in the past two decades, along with the increasing interest in perinatal derivatives, fuels an urgent need for the precise identification of PnD and the establishment of updated consensus criteria policies for their characterization. The aim of this review is not to go into detail on preclinical or clinical trials, but rather we address specific issues that are relevant for the definition/characterization of perinatal cells, starting from an understanding of the development of the human placenta, its structure, and the different cell populations that can be isolated from the different perinatal tissues. We describe where the cells are located within the placenta and their cell morphology and phenotype. We also propose nomenclature for the cell populations and derivatives discussed herein. This review is a joint effort from the COST SPRINT Action (CA17116), which broadly aims at approaching consensus for different aspects of PnD research, such as providing inputs for future standards for the processing and in vitro characterization and clinical application of PnD.

Key Claims

Primary finding · Supported

The literature analysis we performed did not allow us to identify specific markers to uniquely identify the cell populations discussed herein. At the current time, this is a quasi impossible task due to the heterogeneity of the starting material

overlapping and culture-dependent markers support the bounded finding, although unreported literature selection limits completeness

Conclusion, paragraph 1
Quote verified
Secondary · Supported

Incorrect nomenclature and definition of cells ultimately impact the correct identification of the cells and/or derivatives obtained and hinder the direct comparison of results among different research groups.

anatomical and culture examples support the direction, although effects on between-study comparison are not directly measured

Introduction, paragraph 6
Quote verified
Secondary · Tentative

Even though the current cell heterogeneity doesn’t seem to be a limiting factor for functionality and therapeutic efficacy, since preclinical studies and initial clinical trials have demonstrated efficacy of different perinatal cells.

the narrative review does not evaluate whether heterogeneity limits efficacy, and activity across preparations cannot establish that inference

Conclusion, paragraph 3
Quote verified
Secondary · Supported

[In perinatal derivatives research,] the names and abbreviations used to refer to the different cell populations are often misleading and even inappropriate

specific terminology examples support the concern, although no systematic audit establishes its frequency

Conclusion, paragraph 1
Quote verified
Secondary · Supported

Therefore, it is reasonable to believe that hD-preDSC [human decidua predecidual stromal cells] and the hDMSC [human decidua mesenchymal stromal cells] described above belong to the same cell population.

shared phenotype, clonogenicity, perivascular location and differentiation support the cautiously stated cell-identity inference

Human Decidua Mesenchymal Stromal Cells (HDMSC), final paragraph
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Anatomical mapping gives cell names specificity

The review links proposed names to tissue location across fetal membranes, chorionic structures, umbilical cord, amniotic fluid and maternal decidua. This extends the scope of the earlier fetal-membrane guidance.

↳ Introduction; Cells Isolated from the Term Placenta and Fetal Annexes

#positioning

Conflicting findings receive concrete biological explanations

The synthesis explains how culture media and passaging can favour maternal-cell overgrowth and discusses competing interpretations of OCT-4 expression. These examples connect disagreements in the literature to identifiable technical conditions.

↳ Human Chorionic Plate Mesenchymal Stromal Cells; Human Amniotic Membrane Epithelial Cells; Human Amniotic Fluid Cells

#reporting

Developmental sequence makes the synthesis navigable

The text progresses from placental development through early and term anatomy to region-specific cell populations. That sequence helps readers relate the proposed terminology to tissue structure and lineage.

↳ Development of the Human Placenta; Structure of the Early Placenta; Structure of the Term Placenta; Cells Isolated from the Term Placenta and Fetal Annexes

Limitations

#methodological rigour

Source selection and consensus procedures unreported

The article does not explain how literature was identified, selected or evaluated, or how agreement on the nomenclature was reached. Its proposals therefore remain an expert synthesis rather than a transparently derived consensus standard.

↳ Abstract; review as a whole; Conclusion, paragraph 1

#reporting

Therapeutic inference exceeds the reviewed evidence

The conclusion suggests that cell heterogeneity does not limit therapeutic efficacy, despite the review not evaluating that question. Evidence that different preparations show activity does not establish whether heterogeneity reduces efficacy.

↳ Abstract; Conclusion, paragraph 3

#reporting

Dense abbreviations complicate cord region distinctions

The volume of abbreviations and partially overlapping descriptions of cord regions require careful cross-reading. This creates a communication burden in an article intended to reduce terminological confusion.

↳ Human Umbilical Cord; Human Umbilical Cord Wharton’s Jelly Cells; Human Umbilical Cord Perivascular Cells

Does this match your read? Add your assessment ↓

Nabu Commentary

The review's main contribution is a tissue-specific nomenclature roadmap that broadens the earlier fetal-membrane guidance. Its treatment of maternal-cell overgrowth, culture-dependent phenotype and disputed pluripotency markers supports the anatomical synthesis and its qualified conclusion about marker specificity. However, the absence of literature-selection and consensus procedures limits confidence in the derivation of proposed standards. The therapeutic-efficacy inference receives less support than the anatomical conclusions, while dense abbreviations and overlapping cord-region descriptions add a communication burden.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.4±0.2

Contribution
3.7

The review extends the earlier fetal-membrane consensus into an integrated anatomical inventory and naming proposal across perinatal compartments. Its advance is organizational and anatomical rather than a validated set of distinguishing molecular or functional standards.

Introduction; Cells Isolated from the Term Placenta and Fetal Annexes; Conclusion, paragraph 1
Methodological Rigour
3.2

The anatomical sequence and specific treatment of isolation and culture artefacts make the synthesis traceable. Unreported source-selection, evidence-evaluation and consensus procedures limit assessment of how the evidence supports the proposed standards.

Abstract; Human Chorionic Plate Mesenchymal Stromal Cells; Conclusion, paragraph 1
Reporting
3.4

The progression from development to anatomy and cell populations supports navigation, although dense abbreviations and overlapping cord-region descriptions require care. The concluding efficacy inference is stronger than the evidence evaluated in the review.

Human Umbilical Cord; Human Umbilical Cord Perivascular Cells; Abstract; Conclusion, paragraph 3
Positioning
3.5

The review positions its proposal against the 2006 MSC criteria and 2008 placental consensus and integrates conflicting findings on maternal contamination and pluripotency markers. The rationale for choosing among competing anatomical conventions is less fully developed.

Introduction; Human Chorionic Plate Mesenchymal Stromal Cells; Human Amniotic Membrane Epithelial Cells; Human Umbilical Cord

Reliability

No concerns4 of 4 checks


Results checkClean

The reported numbers and statistics are consistent with the stated results.

Reporting and transparencyClean

The article declares no commercial or financial conflicts of interest. No qualifying research-conduct reporting concerns were identified for this narrative review.

Conflict of interest: declared

Reference IntegrityClean

260 references in manuscript 256 of 259 checkable references found in an index 1 are books, websites or datasets — counted, but not index-checkable 3 mistyped DOIs matched to the cited work by its details

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 13 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Generic health relevance
Type of advanceSynthesis
Route to useNamed
AdvanceAdvances
CitationsFWCI 2.0
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessFoundational
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The primary claim rests on a literature analysis and mapping exercise with no experimental demonstration that the nomenclature resolves cell identification in practice.

From the paper
“We also propose the adoption of the herein proposed nomenclature based on the precise tissue and cell localization.”

The paper names who should act (the scientific community and active consortia) and for what purpose (consistent reference to perinatal derivatives toward standardized clinical cell preparation), but without a specific decision setting.

Pathway

Research consortia, cell-processing laboratories and standards bodies would adopt the proposed nomenclature to standardize perinatal cell preparation for regenerative therapies.

Barrier

No unique identifying markers exist and isolation and culture protocols remain unstandardized, so validating and adopting this nomenclature needs coordinated multi-laboratory comparison.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. The fate of human SUSD2+ endometrial mesenchymal stem cells during decidualization

    Tina Gorsek Sparovec, Udo R Markert, Philipp Reif, et al. · 2022 · Basic medicine

    Primary claim

    Our results suggest that SUSD2+ eMSC undergo decidualization in vitro, while maintaining MSC plasma membrane phenotype.

    Tentative
    Evidence Score
    2.5±0.1
    Reliability
    Caveats
  2. Different regulation of IRE1α and eIF2α pathways by oxygen and insulin in ACH-3P trophoblast model

    Veronika Tandl, Denise Hoch, Julia Bandres-Meriz, et al. · 2021 · Basic medicine

    Primary claim

    Overall, our results suggest that IRE1α and eIF2α UPR-pathways are differentially regulated by oxygen and insulin [in ACH-3P trophoblast cells] in early pregnancy.

    Tentative
    Evidence Score
    3.1±0.2
    Reliability
    Caveats
  3. The ALS- and FTD-associated proteins annexin A11 and CHMP2B act sequentially in plasma membrane repair

    Heffner, Starling, Straker, et al. · 2026 · Basic medicine

    Primary claim

    annexin proteins are recruited immediately and form a plug at the damage site, restricting membrane permeability

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats

How the rubric works →